Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dihydroergotamine mesilate intranasal - Satsuma Pharmaceuticals

Next Previous
Drug Profile

Dihydroergotamine mesilate intranasal - Satsuma Pharmaceuticals

Alternative Names: Atzumi; Dihydroergotamine mesilate - Satsuma Pharmaceuticals; Dihydroergotamine mesylate - Satsuma Pharmaceuticals; STS-101; TO-2070

Latest Information Update: 14 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shin Nippon Biomedical Laboratories
  • Developer Satsuma Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Alcohols; Amides; Antimigraines; Benzene derivatives; Ergotamines; Heterocyclic compounds with 4 or more rings; Indoles; Ketones; Mesylates; Oxazolidinones; Piperazines; Piperidines; Pyrrolidines; Quinolines; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Migraine

Most Recent Events

  • 05 Nov 2025 Updated efficacy data from the phase III ASCEND trial in Migraine released by Satsuma Pharmaceuticals
  • 30 Apr 2025 Registered for Migraine in USA (Intranasal)
  • 26 Nov 2024 FDA assigns PDUFA action date of 30/04/2025 for dihydroergotamine mesilate intranasal for Migraine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top